Acadian Asset Management
IBRX icon

Acadian Asset Management’s ImmunityBio IBRX Stock Holding History

Acadian Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,963
Closed -$21K – 1905
2025
Q2 		$21K Hold
7,963
– – ﹤0.01% 1581
2025
Q1 		$23K Buy
+7,963
New +$24.1K ﹤0.01% 1523
2024
Q4 		– Sell
-12,432
Closed -$46K – 1873
2024
Q3 		$46K Buy
+12,432
New +$57.5K ﹤0.01% 1813
2019
Q2 		– Sell
-15,286
Closed -$24K – 1922
2019
Q1 		$24K Buy
+15,286
New +$19.2K ﹤0.01% 1790

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Acadian Asset Management's IBRX Position: Q3 2025 in Review

Acadian Asset Management sold out of ImmunityBio (IBRX) in Q3 2025, closing a stake of 7,963 shares — an estimated $21K sold.

Acadian Asset Management first reported a position in IBRX in Q1 2019 and held it in 4 quarters. The position peaked at $46K in Q3 2024. 263 funds tracked by Wall St. Rank hold IBRX as of Q3 2025.

  • Acadian Asset Management reported no remaining ImmunityBio position as of Q3 2025 after selling out during the quarter.
  • Acadian Asset Management sold 7,963 ImmunityBio shares in Q3 2025, an estimated $21K.
  • Acadian Asset Management first reported a position in ImmunityBio in Q1 2019 and held it in 4 quarters.
  • Acadian Asset Management's ImmunityBio position peaked at $46K in Q3 2024.
  • 263 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2025.

Based on Acadian Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.